Centus Biotherapeutics
http://www.centusbiotherapeutics.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Centus Biotherapeutics
AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar
With the US biosimilar Avastin market now more than a year old, another potential player, Centus Biotherapeutics, finds itself facing trial over its biosimilar candidate. The UK-based joint venture already boasts approval from the European Commission for its FKB238 product, Equidacent.
Centus Gets European Bevacizumab Approval
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Company Information
- Industry
- Biotechnology